

**19 July 2021**

**Market Announcements Office**

**ASX Limited**

### **Update - Notice of Extraordinary General Meeting, scheduled for 2pm on 23 July 2021**

In light of the current outbreak of the Coronavirus (COVID-19) and the New South Wales Government's lockdown response, restricting gatherings, the Company has decided that special arrangements will apply to our upcoming General Meeting on Friday, 23 July 2021 (**Meeting**). Shareholders will not be able to physically attend the Meeting.

The Board considers that the health, safety and welfare of the Company's staff, its Shareholders and other stakeholders is of paramount importance. The Meeting will be accessible to all Shareholders virtually via a live webinar, further details of which are set out below.

All resolutions at the Meeting will be voted on by poll and Shareholders who are entitled to vote may vote either prior to the Meeting by appointing a proxy or by poll during the Meeting (such poll to be taken electronically). Further details of the voting methods open to Shareholders are set out in detail below.

Shareholders are strongly encouraged to either vote prior to the Meeting or to appoint the Chair of the Meeting as their proxy.

#### **How Shareholders Can Participate**

##### ***Voting by Proxy***

Shareholders are strongly urged to appoint the Chair of the Meeting as their proxy. Shareholders can complete the proxy form to provide specific instructions on how a Shareholder's vote is to be exercised on each item of business, and the Chair of the Meeting must follow your instructions. Lodgement instructions (which include the ability to lodge proxies electronically) are set out in the Proxy Form previously despatched to all Shareholders. Proxy votes must be received by 2:00pm (AEST) on Wednesday 21 July 2021.

##### ***Voting by Poll***

Shareholders who wish to vote by poll during the virtual Meeting must first notify the Company Secretary of their intention by email to [jonathan@hera-med.com](mailto:jonathan@hera-med.com) no later than 5.00pm (AEST) on Wednesday, 21 July 2021 and provide the registered Shareholder's Name, Address and HIN or SRN.

Shareholders will be able to submit their email poll votes immediately after the Chair calls for a vote on each Resolution and up to a period of one hour after the Meeting ends. This means that the outcome of each Resolution will not be able to be determined until after the conclusion of the Meeting to allow the Company Secretary sufficient time to count such poll votes submitted by email.

##### ***Questions***

Shareholders may submit questions in advance of the Meeting to the Company Secretary by email to [jonathan@hera-med.com](mailto:jonathan@hera-med.com) by no later than 5.00pm (WST) on Wednesday, 21 July 2021. Shareholders will also have the opportunity to submit questions during the Meeting in respect to the formal items of business as well as general questions in respect to the Company and its operations.

**Webinar**

To facilitate an orderly and secure Meeting, all attendees must register in advance for the webinar at the following link:

[https://us02web.zoom.us/webinar/register/WN\\_XvXIt9CkTGy0Behgi4\\_VCQ](https://us02web.zoom.us/webinar/register/WN_XvXIt9CkTGy0Behgi4_VCQ)

The situation regarding COVID-19 is evolving rapidly and the Company is following the requirements issued by, and the health advice of, the New South Wales and Australian Government. Shareholders are encouraged to monitor the Company's ASX announcements and website for any further updates in relation to arrangements for the Meeting.

Please contact the Company at [Jonathan@hera-med.com](mailto:Jonathan@hera-med.com) if you have any questions.

**Jonathan Hart  
Company Secretary**

This announcement has been authorised by the Board of HeraMED Limited.

**-ENDS-**

**HeraMED Limited**

CEO and Co-Founder

David Groberman

M: +972 52 6991188

E: [David@hera-med.com](mailto:David@hera-med.com)

**Company Secretary**

Jonathan Hart

T: +61 2 7251 1888

E: [Jonathan@hera-med.com](mailto:Jonathan@hera-med.com)

**Investor Enquiries**

Tim Chapman

Pac Partners

M: +61 419 897 062

E: [tchapman@pacpartners.com.au](mailto:tchapman@pacpartners.com.au)